BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 36870519)

  • 21. Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases.
    Li X; Xia C; Liu M; Liu J; Dong M; Zhao H; Xu S; Wang D; Wei S; Song Z; Chen G; Liu H; Chen J
    Front Oncol; 2022; 12():843116. PubMed ID: 36176413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial.
    Yan W; Zhong WZ; Liu YH; Chen Q; Xing W; Zhang Q; Liu L; Ge D; Chen K; Yang F; Lin X; Song L; Shi W; Wu YL
    J Thorac Oncol; 2023 Feb; 18(2):194-203. PubMed ID: 36191882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study.
    Pu X; Lin G; Xiao M; Lin J; Wang Q; Kong Y; Yan X; Xu F; Xu Y; Li J; Li K; Chen B; Wen X; Tan Y; Cheng F; Zhu K; Li N; Wu L
    EClinicalMedicine; 2024 Jan; 67():102403. PubMed ID: 38261958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma.
    Liu J; Yang Y; Liu Z; Fu X; Cai X; Li H; Zhu L; Shen Y; Zhang H; Sun Y; Chen H; Yu B; Zhang R; Shao J; Zhang M; Li Z
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma.
    Ju WT; Xia RH; Zhu DW; Dou SJ; Zhu GP; Dong MJ; Wang LZ; Sun Q; Zhao TC; Zhou ZH; Liang SY; Huang YY; Tang Y; Wu SC; Xia J; Chen SQ; Bai YZ; Li J; Zhu Q; Zhong LP
    Nat Commun; 2022 Sep; 13(1):5378. PubMed ID: 36104359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer.
    Rusch VW; Nicholas A; Patterson GA; Waqar SN; Toloza EM; Haura EB; Raz DJ; Reckamp KL; Merritt RE; Owen DH; Finley DJ; McNamee CJ; Blasberg JD; Garon EB; Mitchell JD; Doebele RC; Baciewicz F; Nagasaka M; Pass HI; Schulze K; Johnson A; Bunn PA; Johnson BE; Kris MG; Kwiatkowski DJ; Wistuba II; Chaft JE; Carbone DP; Lee JM
    J Thorac Cardiovasc Surg; 2023 Mar; 165(3):828-839.e5. PubMed ID: 36369159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial.
    Zhu X; Sun L; Song N; He W; Xie B; Hu J; Zhang J; Yang J; Dai J; Bian D; Xia H; Sun F; Xiong A; Luo J; Zhang L; Yu H; Liu M; Liu H; Wang H; Zhang H; Chen C; Wu C; Duan L; Zhu Y; Zhang P; Jiang G
    BMC Med; 2022 Dec; 20(1):493. PubMed ID: 36581917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
    Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose apatinib combined with camrelizumab and the SOX regimen in the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (SPACE-neo): a protocol for an open-label, single-arm, clinical trial.
    Pan L; Tian Y; Wang K; Tang J; Liu J; Zhang J; Wang M; Liu J; Xu H; Chen X
    J Gastrointest Oncol; 2022 Dec; 13(6):3300-3313. PubMed ID: 36636043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring
    Gao G; Ni J; Wang Y; Ren S; Liu Z; Chen G; Gu K; Zang A; Zhao J; Guo R; He J; Lin X; Pan Y; Ma Z; Wang Z; Fan M; Liu Y; Cang S; Yang X; Li W; Wang Q; Zhou C
    Transl Lung Cancer Res; 2022 Jun; 11(6):964-974. PubMed ID: 35832447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The outcome and safety of neoadjuvant PD-1 blockade plus chemotherapy in stage Ⅱ~Ⅲ non-small cell lung cancer].
    Liu YT; Gao YS; Mao YS; Jiang J; Yang L; Yang JL; Hu XS; Zhou SY; Qin Y; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):480-485. PubMed ID: 32575944
    [No Abstract]   [Full Text] [Related]  

  • 32. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
    Zhou C; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Wu F; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J;
    Lancet Respir Med; 2021 Mar; 9(3):305-314. PubMed ID: 33347829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study.
    Zhou RQ; Luo J; Li LJ; Du M; Wu QC
    BMC Surg; 2023 May; 23(1):114. PubMed ID: 37161374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma.
    Xu H; Wang W; Yin J; Song C; Li L; Sun Z
    Drug Des Devel Ther; 2022; 16():4269-4277. PubMed ID: 36540715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study.
    Liu J; Li J; Lin W; Shao D; Depypere L; Zhang Z; Li Z; Cui F; Du Z; Zeng Y; Jiang S; He P; Gu X; Chen H; Zhang H; Lin X; Huang H; Lv W; Cai W; Liang W; Liang H; Jiang W; Wang W; Xu K; Cai W; Wu K; Lerut T; Fu J; He J
    Int J Cancer; 2022 Jul; 151(1):128-137. PubMed ID: 35188268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
    Provencio M; Nadal E; Insa A; García-Campelo MR; Casal-Rubio J; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Pereira E; Royuela A; Casarrubios M; Salas Antón C; Parra ER; Wistuba I; Calvo V; Laza-Briviesca R; Romero A; Massuti B; Cruz-Bermúdez A
    Lancet Oncol; 2020 Nov; 21(11):1413-1422. PubMed ID: 32979984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy.
    Xing P; Wang M; Zhao J; Zhong W; Chi Y; Xu Z; Li J
    Thorac Cancer; 2021 Oct; 12(20):2825-2828. PubMed ID: 34409776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study.
    Wang J; Zhang J; Gao J; Zhao M; Ma Z
    Adv Clin Exp Med; 2023 Sep; ():. PubMed ID: 37676100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial.
    Lv C; Fang W; Wu N; Jiao W; Xu S; Ma H; Wang J; Wang R; Ji C; Li S; Wang Y; Yan S; Lu F; Pei Y; Liu Y; Yang Y
    Lung Cancer; 2023 Apr; 178():151-156. PubMed ID: 36863124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial.
    Ren S; He J; Fang Y; Chen G; Ma Z; Chen J; Guo R; Lin X; Yao Y; Wu G; Wang Q; Zhou C
    JTO Clin Res Rep; 2022 May; 3(5):100312. PubMed ID: 35498381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.